encoded by AKR1C3 gene, plays a pivotal role in both androgen and estrogen metabolism and its deregulated expression was found in different cancers. In this study we measured AKR1C3 transcript and protein levels in nontumoral and primary tumoral gastric tissues and evaluated their association with some clinicopathological features of gastric cancer (GC). We found decreased AKR1C3 transcript (p<0.0001) and protein (p=0.0021) levels in GC tissues compared to adjacent histopathologically normal appearing mucosa. Lower levels of AKR1C3 transcript were observed in diffuse and intestinal types of GC whereas AKR1C3 protein was decreased in tumors with multi site localization, in diffuse histological type, T3, T4 and G3 grades. We also determined the effect of histone deacetylases inhibitor, sodium butyrate (NaBu), on AKR1C3 expression in EPG 85-257
and experimental studies indicate on steroid hormones as a possible factor related to this carcinoma (Camargo et al. 2011 ). Estrogens seem to have a protective effect in GC etiology, according to the higher incidence of that tumor in males than females (Camargo et al. 2011) . Role of androgens in GC etiology is a less elucidated and only a few studies concern that issue (Nakamura et al. 2006; Polimeno et al. 1994) . Important findings in the sex steroid biology is the ability of some peripheral tissues to conversion of adrenal derived dehydroepiandrosterone, its sulfate and androstenedione (a-dione) into an active estrogens and androgens (Sasano et al. 1998; Labrie and Labrie 2013) .
These hormones exert their action on the same cells where its synthesis took place, without a release to the general circulation. The peripheral synthesis rate of steroid hormones is controlled by the local expression of enzymes which synthesize the estrogens and androgens from adrenal derived precursors (Labrie et al. 2000) . Aberrant expression of enzymes involved in local steroidogenic pathway may lead to the formation of an abnormal intracellular steroids level and to uncontrolled cells proliferation (Brodie et al. 2009 ). Some evidence suggest, that changes in the expression of genes encoding steroidogenic enzymes could have a significant meaning in the etiology of hormone dependent tumors, including breast (Sasano et al. 2006) , endometrial (Sasano et al. 2000) , ovarian (Mungenast and Thalhammerand 2014), prostate (Gianfrilli et al. 2014) as well as in the other tumors not directly related with reproductive features like lung (Drzewiecka et al. 2015) , thyroid (Rahbari et al. 2010) , colon (Lin and Giovannucci 2010), central nervous system ( Park et al. 2010 ), or gastric (Nakamura et al. 2006 Frycz et al. 2015) . One of the most important enzymes family, responsible for the interconversion between the biologically active and inactive forms of estrogens and androgens on the last steps of their biosynthesis, are 17B-hydroxysteroid dehydrogenases (HSD17Bs).
There are 14 type of HSD17Bs reported of which 12 have been found in humans. HSD17Bs isoenzyme differ with the substrate specificity and tissue pattern expression (Moeller and Adamski D r a f t 2009). Additionally, it was shown that the expression of AKR1C3 gene encoding type 5 of HSD17B, responsible for the conversion of both, a-dione to testosterone (T) and estrone (E1) to 17β-estradiol (E2), is deregulated in multiple human cancers (Dozmorov et al. 2010; Lewis et al. 2004; Zakharov et al. 2010; Martinez et al. 2007) . Therefore, according to the emerging role of steroid hormones in GC development, we measured transcript and protein levels of AKR1C3 in nontumoral and in primary tumoral gastric tissues. We also assessed the effect of histone deacetylases inhibitor, sodium butyrate (NaBu), on the AKR1C3 transcript and protein levels in EPG 85-257 and HGC-27 GC cell lines. Additionally, we evaluated the association of AKR1C3 expression with some clinicopathological features of GC.
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Materials and methods
Tissue specimens
Primary tumoral gastric tissues and adjacent histopathologically normal appearing mucosa were 
Antibodies and Reagents
Goat polyclonal anti-AKR1C3 antibody (Ab) (ab27491) was purchased from Abcam, (Cambridge, UK 
Proliferation and viability assaying of the EPG 85-257 and HGC-27 GC cells after NaBu treatment
After respective time of incubation, the cells were harvested and total number of viable and dead cells were counted with trypan blue dye. Total cells number, stained and unstained, was represented as a percent of respective control for proliferation assay. Cells viability was calculated with using following equation: total viable cells (unstained)/total cells (stained and ustained) x 100 and represented as a percent of respective control. Each sample was determined in triplicate and results are presented as the mean ± SD from three experiments
Reverse transcription and real-time quantitative polymerase chain reaction (RQ-PCR) analysis of the
AKR1C3 transcript levels
The total RNA from the primary tissue of patients with GC as well as from EPG 85-257 and HGC-27
GC cells was isolated according to the method of Chomczyński and Sacchi (2006) . Purity and integrity of RNA was assessed with using Nano-100 spectrophotometer (Hangzhou Allsheng, China) D r a f t and gel electrophoresis respectively. RNA samples were treated with DNase I, quantified, and reversetranscribed into cDNA. RQ-PCR was carried out in a Light Cycler real-time PCR detection system from Roche Diagnostics GmbH, (Mannheim, Germany) using SYBR® Green I as detection dye.
The transcript levels in patient tissues were expressed as multiplicity of these cDNA concentrations in the calibrator. In EPG 85-257 and HGC-27 GC cells, these transcript levels were presented as multiplicity of the respective controls. The calibrator was prepared as cDNA mix from all of the patient samples and successive dilutions were used to create the standard curve as is described in
Relative Quantification Manual Roche Diagnostics GmbH, (Mannheim, Germany). For amplification, 1µl of cDNA solution was added to 9µl of Light Cycler®480 SYBR Green I Master mix (Roche, Mannheim, Germany) contained the following primers sequences: AKR1C3 forward:
5'-GGGATCTCAACGAGACAAAC-3' and reverse: 5'-AAAGGACTGGGTCCTCCAAG-3'.
The quantity of AKR1C3 transcripts in each sample was standardized by the geometric mean of beta-2-microglobulin (B2M) and beta-glucuronidase (GUSB) cDNA levels and expressed as multiples of these cDNA in the calibrator.
Western blotting analysis
The tissue of patients as well as EPG 85-257 and HGC-27 GC cells were treated with lysis RIPA buffer for proteins isolation. Then, 40µg of protein were resuspended in sample buffer and separated on 12% Tris-glycine gel using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Gel proteins were transferred to nitrocellulose membrane, which was next blocked with 5% milk in Tris/HCl saline/Tween buffer. Immunodetection of the bands was performed with goat polyclonal anti-AKR1C3 Ab, followed by incubation with rabbit anti-goat HRP-conjugated Ab.
To ensure equal protein loading of the lanes, the membrane was re-stripped and incubated with rabbit polyclonal anti-GAPDH Ab and goat anti-rabbit HRP-conjugated Ab. Bands were revealed using ECL kit and Hyperfilm ECL Amersham (Piscataway, NJ). The amount of AKR1C3 protein was calculated as the AKR1C3 to GAPDH band optical density ratio. 
Effect of NaBu on the proliferation and viability of EPG 85-257 and HGC-27 GC cells
NaBu significantly inhibited the proliferation ( 
Effect of NaBu on AKR1C3 transcript and protein levels in EPG 85-257 and HGC-27 GC cells
We were able to detect AKR1C3 protein which was confirmed by positive control-MCF7 protein lysate. However, we also observed an unspecific protein band above AKR1C3 band in some tissues and GC cell lines. This unspecific signal was not analyzed. We observed increase of AKR1C3 transcript ( Strong AKR1C3 positive immunoreactivity was also demonstrated in the nontumoral gastric mucosal cells, lining close to the luminal surface but no or weak immunoreactivity was presented in deeply located epithelial cells such as those in the gastric pits (Chang et al. 2013 ).
Since we used homogenized control mucosa containing both types of these cells, our results could be limited by the method we used. Moreover, in contrast to the previous results, the same study showed strong AKR1C3 positive immunoreactivity in GC tissues. On the other hand, this study was limited by relative small number of examined cases (9 gastric adenocarcinomas).
Immunoreactivity of AKR1C3 in tumoral gastric tissues was also demonstrated
by Nakamura et al. (2006) . However, due to simultaneous presence of this enzyme in nontumoral adjacent mucosa, authors suspected limited AKR1C3 contribution to the development of GC.
Up-regulation of AKR1C3 transcript and protein levels were widely shown in breast (Lin et al. 2004; Vihko et al. 2005; Jansson et al. 2006; Suzuki et al. 2007 ) and prostate (Fung et al. 2006; Stanbrough et al. 2006; Locke et al. 2008; Wako et al. 2008; Pfeiffer et al. 2011; Hamid et al. 2013 ) tumoral tissues which are known to be steroid sensitive. Thus an over-expression of AKR1C3 could facilitate the growth of those tumors by increasing the intratissue level of active steroids. Additionally, LNCaP prostate cancer cells with AKR1C3 over-expression were shown to synthesize higher amounts of T which results an increased of their proliferation rate (Byrns et al. 2012 ).
In our study, we showed that decreased AKR1C3 transcript levels were significantly associated with diffuse and intestinal type of GC. Lowered AKR1C3 protein levels were also significantly correlated with multi site localization, diffuse histological type, T3 and T4 grades of tumor depth and G3, 2012), steroid synthesis mediated by AKR1C3 could be significant for GC development. Moreover, epidemiological and experimental studies show estrogens, including E2, as protective agents in GC etiology (Freedman et al. 2007; Camargo et al. 2011) . Additionally, in our previous study we presented that GC cells are able to convert E1 into E2 by HSD17B1 action (Frycz et al. 2013 ). On the other hand, the role of androgens during gastric carcinogenesis still remains unknown. However, there are studies suggesting an oncogenic potential of androgens in GC (Nakamura et al. 2006; Tian et al. 2013 ). In our recent work, we showed that the amount of HSD17B2 protein, which acts in opposite to AKR1C3, is also reduced in tumoral tissues of patients with GC (Frycz et al. 2015) .
The decreased expression of HSD17B2 could results in an elevation of E2 and T in tumoral gastric tissues. Thus, an inhibition of E1 to E2 conversion by down-regulation of AKR1C3 and an elevation of T level in tumoral tissue maintained by HSD17B2 down-regulation can enhance gastric carcinogenesis. Although, T synthesis can be also mediated by AKR1C3 enzyme, in vitro studies showed, that MCF7 breast cancer cells with stabled AKR1C3 expression presented increased steroid conversion leading to pro-estrogenic state and surprisingly, E1 was revealed to be reduced faster than other substrates, including a-dione (Byrns et al. 2009 ). Moreover, AKR1C3 posses reductive activity which partly inactivates 5α-dihydrotestosterone (DHT), the most biologically potent androgen, to the weak androgens 3α-androstanediol and 3β-androstanediol ( Steckelbroeck et al. 2003) .
Thus, tissues substrate specify of this enzyme must be clarified for better understanding of its involvement in GC development. Notably, T can be converted into E2 through aromatase (CYP19) enzyme which is known to be expressed in nontumoral and tumoral gastric mucosa (Izawa et al.
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of E2/T ratio, could be also caused by the presence of single nucleotide polymorphisms (SNPs) in the sequences of their genes (Rossi et al. 2003) . As an example, some SNPs of CYP19 were significantly associated with increased risk of GC (Cho et al. 2012) . So far, we don't know any data showing the association of AKR1C3 polymorphism with GC risk. However, such correlation was showed in prostate cancer (Schulze et al. 2012 ).
Except its role in steroid conversion, AKR1C3 enzyme is able to synthesize prostaglandin F by the conversion of prostaglandin H2 to prostaglandin F2α (PGF2α) and prostaglandin D2 to 9α, 11β-prostaglandin F2 (Matsuura et al. 1998; Suzuki-Yamamoto et al. 1999) . Nakamura et al. also down-regulation of focal adhesion kinase protein and finally, leaded to cells apoptosis . Similarly, in our study NaBu significantly decreased proliferation and viability of both, EPG 85-257 and HGC-27 GC cells in dose and time dependent manner. The decreased proliferation and viability of HGC-27 GC cells, caused by NaBu mediated increase in phosphatase and tensin homolog expression, was previously shown by Pan et al. (2010) . We also demonstrated, that NaBu is able to up-regulate transcript and protein of AKR1C3 in EPG 85-257 and HGC-27 GC cells.
To the best of our knowledge, there are no studies which have shown the regulation of AKR1C3
by NaBu, however this compound was able to influence the expression of other genes involved in steroidogenesis. The NaBu mediated up-regulation of HSD17B1 mRNA and protein levels was observed in colorectal cancer cell lines -HT29 and SW707 (Rawłuszko et al. 2011 AKR1C3 cDNA levels were expressed as a multiplicity of the respective controls. Each sample was determined in triplicate and results are presented as the mean ± SD from three experiments. *p<0.05; **p<0.01; ***p<0.001. The quantity of AKR1C3 transcripts in each sample was standardized by the geometric mean of B2M and GUSB cDNA levels and expressed as multiples of these cDNA in the calibrator. The amount of AKR1C3 protein was calculated as the AKR1C3 to GAPDH band optical density ratio. The "p" value was evaluated by Mann-Whitney Test. 263x186mm (300 x 300 DPI) D r a f t Fig. 2 . NaBu inhibits proliferation (A,C) and viability (B,D) in EPG 85-257 and HGC-27 GC cells respectively. The cells were incubated for 24-78 hours and treated with the different concentrations of NaBu. After incubation, the cells were harvested and the total number of both, viable (unstained) and unviable (stained) cells were calculated with using trypan blue dye. Proliferation rate of EPG 85-257 (A) and HGC-27 (C) cells was represented as percent of total (stained and unstained) cell numbers of respective control. EPG 85-257 (B) and HGC-27 (D) GC cells viability was calculated with using following equation: total viable cells (unstained)/total cells (stained and ustained) x 100 and represented as a percent of respective control. Each sample was determined in triplicate and results are presented as the mean ± SD from three experiments. *p<0.05; **p<0.01; ***p<0.001. 64x48mm (300 x 300 DPI) D r a f t Fig. 3 . NaBu increases AKR1C3 transcript levels in EPG 85-257 (A) and HGC-27 (B) GC cells. The cells were cultured for 72 hours in an appropriate phenol red-free medium either in the absence (0.0) or in the presence of NaBu at the concentrations of 2.0, 5.0 and 8.0mM for EPG 85-257 and 0.5, 1.5 and 3.0mM for HGC-27 GC cells. After incubation, the cells were used for total RNA isolation and reverse transcription. The AKR1C3 cDNA levels were determined by RQ-PCR relative quantification analysis. RQ-PCR results were standardized by the geometric mean of B2M and GUSB cDNA levels. AKR1C3 cDNA levels were expressed as a multiplicity of the respective controls. Each sample was determined in triplicate and results are presented as the mean ± SD from three experiments. *p<0.05; **p<0.01; ***p<0.001. 190x247mm (300 x 300 DPI) D r a f t Fig. 4 . NaBu increased AKR1C3 proteins level in EPG 85-257 (A) and HGC-27 (B) GC cells. The cells were cultured for 24, 48 and 72 hours in an appropriate phenol red-free medium either in the absence or in the presence of NaBu at the concentrations of 2.0, 5.0 and 8.0mM for EPG 85-257 and 0.5, 1.5 and 3.0mM for HGC-27 GC cells. The cells protein were separated by 12% SDS-PAGE, and transferred to a membrane that was then immunoblotted with rabbit polyclonal anti-AKR1C3 Ab and incubated with goat anti-rabbit HRPconjugated Ab. After stripping, the membrane was reblotted with rabbit polyclonal anti-GAPDH Ab and goat anti-rabbit HRP-conjugated Ab. The band densitometry readings were normalized to GAPDH loading control.
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